Aminosalicylate Use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease.
文献摘要
Background & aims Despite lack of evidence for efficacy, 5-aminosalicylates (5-ASAs) continue to be prescribed for pediatric Crohn's disease (pCD). There are limited data examining current practice patterns in pCD and the impact of 5-ASAs use on clinical outcomes. We aimed to determine the prevalence of 5-ASAs use in pCD and evaluate its association with biologic durability, corticosteroid exposure, and disease-related complications. Methods We conducted a prospective, multicenter inception cohort study using data from the Biologic dISContinuation sTudy (BISCUIT). Early therapy ( Results Of 679 patients, 18% received early 5-ASA monotherapy. Early 5-ASAs were associated with greater systemic corticosteroid use (P = .036) and delayed time-to-biologic (median, ∼11 months), with 58.0% of patients escalating therapy. Among those who escalated, early 5-ASAs increased the risk of biologic discontinuation (hazard ratio, 4.47; 95% confidence interval, 1.28-15.65; P = .029). Furthermore, early 5-ASA and immunomodulator use did not prevent disease complications, whereas early anti-tumor necrosis factor therapy protected against perianal disease (odds ratio, 0.24; 95% confidence interval, 0.06-0.93; P = .039). Conclusions Early 5-ASAs use in patients with pCD is common, represents undertreatment, and is associated with inferior outcomes, including greater steroid exposure, delayed initiation of effective biologic therapy, and decreased biologic durability, without protection against disease complications. These findings support avoidance of 5-ASAs in patients with pCD and prioritizing early anti-tumor necrosis factor therapy to improve long-term outcomes and reduce perianal disease risk.